In recent trading, Clover Health Investments Corp (CLOV) stock price has shown some volatility, fluctuating 3.25% over the last five trades and 34.44% over the past 30 trades. This represents a ...

In terms of valuation, Vincerx Pharma Inc’s market capitalization stands at $3.62 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market ...

The scale of infections has led to predictions of very high sales for the first RSV vaccines to reach the market, with analysts at SVB Leerink predicting the market could reach upwards of $10 ...

SVB Leerink’s Geoffrey Porges notes that large biopharma deals “arise from a position of distress, not strength”, and on that front that Gilead is “far from distressed.” The biopharma ...

Roche Holding AG Akt 0.56% CHF214.52B ...

Wednesday after the company’s fourth-quarter print. Stryker reported quarterly earnings of $4.01 per share, which beat the ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Leerink analyst Joseph Schwartz notes Outperform-rated Sarepta (SRPT) disclosed two-year Part 1 and one-year Part 2 data from the EMBARK study with Elevidys. The firm views these topline results ...

Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at $1.61 EPS, FY2028 earnings at $4.55 EPS and FY2029 ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $70.37 ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...